#chronic lymphocytic leukemia

The Latest Advancements in Immunotherapy for Adult Leukemia

September was designated as National Blood Cancer Awareness Month in 2010 by United States Congress.

The combination of chemoimmunotherapy with a targeted drug represents a step toward a new standard of care for people with CLL.

“Radiation can cause cancer and non-cancer outcomes, but it does not cause every type of cancer and non-cancer outcome.”

Targeted therapy combination reduced the risk of disease progression or death by 65% in a randomized study.

Study found Venclexta plus Gazyva (obinutuzumab) delayed disease progression in previously untreated patients.

Imbruvica plus Gazyva is the first chemotherapy-free regimen for chronic lymphocytic leukemia.

Imbruvica plus Gazyva is the first chemotherapy-free regimen for chronic lymphocytic leukemia.

Venclexta alone or in combination with Rituxan improved progression-free survival in patients with chronic lymphocytic leukemia.

Imbruvica-based treatment may also work better than intensive chemotherapy for younger patients.

Customized cell therapy plus Imbruvica leads to high response rate.

Venclexta plus Gazyva reduces risk of disease progression or death.

Here’s a list of approved drugs to treat leukemia including acute lymphocytic or lymphoblastic leukemia (ALL), chronic lymphocytic le...

INVAC-1 vaccine targets the telomerase enzyme involved in cancer cell growth.